In the recently-completed Collective Bargaining Agreement, the league and the union agreed to make several modifications to the Joint Drug Agreement which governs drug testing, suspensions and whatnot in baseball. They just announced that they have reached agreement on the modifications.
They’re all listed below. The ones that seem notable or major to me in bold. Many of them are designed to specifically address the Ryan Braun fiasco from this spring:
- Adding hGH blood testing during Spring Training, during the off-season, and for reasonable cause. The parties also agreed to study expanding hGH testing to the regular season.
- Increasing the number of random tests during the season and off-season.
- Modifying the Collection Procedures of the Program to clarify when collectors must deliver specimens to the courier, and how specimens should be stored prior to delivery to the courier.
- Modifying the Appeals procedures of the Program, including the circumstances under which procedural deviations will result in the invalidation of test results.
- Creating an Expert Panel of recognized ADD/ADHD experts to advise the Independent Program Administrator (“IPA”) on Therapeutic Use Exemption (“TUE”) applications for ADD/ADHD medications, and another expert panel of medical professionals to advise the IPA on TUE applications for other medications.
- Strengthening the protocols for addressing use by players of drugs of abuse.
- Permitting public announcement of the specific substance that resulted in a player’s positive test result or discipline.
- Making players who are suspended for violating the Program prior to the All-Star Break (including during Spring Training and the preceding off-season) ineligible to be elected or selected for the All-Star Game.
- Establishing a protocol for evaluating and treating players who may suffer from an alcohol use problem or who have engaged in off-field violent conduct.
- Clarifying the rules for violations for use or possession of prohibited substances based on evidence other than positive test results (“non-analytical positives.”)
- Increasing the penalties for criminal convictions for possession or use of drugs of abuse (including stimulants).
Some of these, such as the no-All-Star Game for those who test positive thing have been long sought-after. I’ll also note, building on yesterday’s post, that while there is now something for evaluating people with alcohol problems, and something about increasing discipline for drug convictions, there is nothing about DUI incidents or convictions. So close, guys!
According to Jorge Castillo of the Washington Post, Nationals infielder Danny Espinosa declined to attend the team’s annual Winterfest because of his dissatisfaction with management following their trade for outfielder Adam Eaton.
A source told Castillo that Espinosa’s unhappiness stemmed from a belief that the acquisition would jeopardize his starting role in 2017. With Eaton in center field, Trea Turner will likely return to his post at shortstop, leaving Espinosa out in the cold — or, as the case may be, on the bench. The move shouldn’t come as a big surprise to Espinosa, however, as Nationals’ GM Mike Rizzo spoke to the possibility of trading the infielder or reassigning him to a utility role back in early November.
Offensively, the 29-year-old had a down year in 2016, slashing just .209/.306/.378 with 24 home runs in 601 PA. Defensively, he still profiles among the top shortstops in the National League, with eight DRS (Defensive Runs Saved) and 8.3 Def (Defensive Runs Above Average) in his seventh year with the club.
Espinosa will reach free agency after the 2017 season.
The Red Sox might be trying to move the wrong pitcher, according to the Boston Globe’s Nick Cafardo. Cafardo revealed that while the Sox have been trying to market right-hander Clay Buchholz, more teams would be interested in trades involving southpaw Drew Pomeranz.
The club appears reluctant to deal Pomeranz, especially because his price tag comes in at a cool $4.7 million to Buchholz’s $13.5 million in 2017. Those who have already expressed interest in the veteran hurlers, including the Twins, Mariners and Royals, also seem put off by Buchholz’s salary requirements as he enters his 32nd year.
Health could be another factor preventing teams from jumping to make trade offers, as Cafardo quotes an AL executive who believes the “medicals on both Pomeranz and Buchholz probably aren’t that great.” Neither pitcher suffered any major injuries during the 2016 season, though Pomeranz missed just over a week of play due to forearm soreness.
Pomeranz outperformed his fellow starter in 2016, pitching to a 3.32 ERA and career-best 9.8 K/9 through 170 2/3 innings with the Padres and Red Sox. He got off to an exceptionally strong start in San Diego, where his ERA dropped to 2.47 through the first half of the year before the Padres dealt him to Boston for minor league right-hander Anderson Espinoza. Buchholz, on the other hand, struggled with a 4.78 ERA and saw a decline in both his BB/9 and K/9 rates as he worked out a career-low 1.69 K/BB through 139 1/3 innings with the Sox.